Q-omics provides the consensus-scored MIR532 profile across patient tissues and cancer cell-line models. MIR532 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR532 is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, MIR532 RNA expression shows 8,714 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight SKCM, ESCA, and COAD as cancer lineages where MIR532 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR532 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR532 survival associations across molecular data types. MIR532 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR532 RNA expression–survival associations across cancer types. High MIR532 expression shows unfavorable associations in SKCM, BLCA, BRCA, UCEC, ESCA and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR532 RNA expression.
This table summarizes MIR532 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR532. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR532 shows higher tumor expression in ESCA. The ESCA box plot shows higher MIR532 RNA expression in tumor versus normal tissue (log2 FC = +1.225, t-test p = .011).
This table shows molecular features associated with MIR532 in patient tissues and cancer cell lines. In patient samples, MIR532 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
